Radiation plus immunotherapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether a more intensive form of targeted radiation, combined with immunotherapy (immune checkpoint inhibitors), can work better and be safe for people with advanced non-small cell lung cancer. You may be considered if your tumor is limited in size and you’re able to receive both treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to sign consent and follow the study plan.
- You have non-small cell lung cancer that is stage IIIB or higher, confirmed by biopsy.
- Your age must be 18 to under 75, and your daily functioning score (ECOG) must be 0 to 3.
- Your cancer must fit targeted radiation rules: the tumor is limited in size (under 5 cm).
- You should be able to receive immune checkpoint inhibitor treatment and stereotactic (targeted) radiation.
- You likely cannot have recent serious infection, major liver or kidney problems, or conditions that prevent either treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced non-small cell lung cancer whose tumors responded well to initial chemo-immunotherapy. Instead of giving full chest radiation, doctors will only target the main tumor to see if it can prevent regrowth with fewer side effects.
This trial tests a new type of radiation combined with immunotherapy for people with advanced solid tumors that are no longer responding to standard treatments or cannot tolerate them. The goal is to see if this combination can help control the disease.
This trial tests whether adding low-dose radiation and a type of targeted radiation (SBRT) to a combination of immunotherapy (sintilimab) and chemotherapy works better than immunotherapy and chemotherapy alone for people with advanced squamous cell lung cancer.
This trial explores whether combining radiation therapy with immunotherapy can trigger an immune response that shrinks tumors throughout the body (abscopal effect) in people with non-small cell lung cancer that has spread to 3 to 6 other sites. It tests different patterns of these treatments to see which works best.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
This trial tests combining a type of radiation therapy called SBRT with an immunotherapy drug called puterizumab for patients whose non-small cell lung cancer has spread to the lungs after prior immunotherapy. The goal is to see if this combination can help control the cancer.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.